Ipamorelin: Benefits, Dosage & FDA Status
Ipamorelin Acetate
A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
FDA Status
Not FDA-approved — Category 1 (compounding allowed)
Typical Dose
100–300 mcg before bed (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Half-Life
~2 hours
Routes of Administration
subcutaneous
First Synthesized
1998
Clinics Indexed
195 providers have offered Ipamorelin in our tracked directory.
Mechanism of Action
Pentapeptide ghrelin/GHS-receptor agonist driving pulsatile GH release without the appetite, cortisol, or prolactin elevations of older GHRPs.
Key Reported Benefits
- ✓Clean GH release
- ✓Improved sleep quality
- ✓Fat reduction
- ✓Joint health
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Reported Side Effects
- •Injection-site reactions
- •Mild head-rush
- •Hunger spikes (rare)
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy / breastfeeding
Commonly Stacked With
CJC-1295 (no DAC)
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Tesamorelin
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 1 (compounding allowed)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Ipamorelin. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Sermorelin
B+The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
MK-677
B+An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
GHRP-2
BA potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.
GHK-Cu
B+A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.